PARP inhibitors are a new area in the treatment of breast cancer

The paper considers the use of poly(ADP-ribose)-polymerase inhibitors in therapy for breast and ovarian cancer. Particular attention is given to drugs, such as olaparib and BSI-201. It is noted that the emergence of drugs of this class, of course, holds great promise for using remedial measures and...

Full description

Bibliographic Details
Main Author: V. P. Letyagin
Format: Article
Language:Russian
Published: ABV-press 2014-08-01
Series:Опухоли женской репродуктивной системы
Subjects:
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/260